Amendments to the Claims

The listing of claims will replace all prior versions, and listing of claims in the application.

Listing of Claims

1-12. (Canceled).

13. (Currently Amended) A method of treating an affective disorder which comprises administering to a patient ~~in need of such treatment or prevention~~ a therapeutically ~~or prophylactically~~ effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, wherein the affective disorder is alcohol addiction, an anxiety disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, narcolepsy, seasonal affective disorder, or premenstrual syndrome.

14. (Original) The method of claim 13 wherein the bupropion metabolite is optically pure.

15. (Previously presented) The method of claim 14 wherein the optically pure bupropion metabolite is optically pure (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol.

16-57. (Canceled).

58. (Previously presented) The method of claim 14 wherein the optically pure bupropion metabolite is (R,R)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol; (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol; (R,R)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (S,R)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (S,S)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (R,S)-2-(*tert*-butylamino)-1-(3-chlorophenyl)-propan-1-ol; (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone; or (R)-1-(3-chlorophenyl)-2-[(1,1-dimethylethanol)amino]-1-propanone.

59. (Previously Presented) The method of claim 13 wherein adverse effects associated with the administration of racemic bupropion are reduced or avoided.

60. (Canceled).

61. (Previously presented) The method of claim 13 wherein the effective amount of the bupropion metabolite is from about 1 mg to about 750 mg per day.

62. (Previously presented) The method of claim 13 wherein the effective amount of the bupropion metabolite is from about 5 mg to about 700 mg per day.

63. (Previously presented) The method of claim 13 wherein the effective amount of the bupropion metabolite is from about 10 mg to about 650 mg per day.

64. (Previously presented) The method of claim 13 wherein the bupropion metabolite is administered orally, transdermally, and mucosally.

65. (Previously presented) The method of claim 64 wherein the bupropion metabolite is administered orally.

66. (Previously presented) The method of claim 64 wherein the bupropion metabolite is administered transdermally.

67. (Previously presented) The method of claim 64 wherein the bupropion metabolite is administrated mucosally.

68. (Previously presented) The method of claim 13 wherein the affective disorder is alcohol addiction.

69. (Previously presented) The method of claim 13 wherein the affective disorder is an anxiety disorder.

70. (Previously presented) The method of claim 13 wherein the affective disorder is a bipolar or manic condition.

71. (Previously presented) The method of claim 13 wherein the affective disorder is bulimia.

72. (Previously presented) The method of claim 13 wherein the affective disorder is chronic fatigue syndrome.

73. (Previously presented) The method of claim 13 wherein the affective disorder is narcolepsy.

74. (Previously presented) The method of claim 13 wherein the affective disorder is seasonal affective disorder.

75. (Previously presented) The method of claim 13 wherein the affective disorder is premenstrual syndrome.

76. (Previously presented) The method of claim 13 wherein the bupropion metabolite is in the form of an acceptable salt.

77. (Previously presented) The method of claim 13 wherein the bupropion metabolite is in the form of a solvate.

78. (Previously presented) The method of claim 13 wherein the bupropion metabolite is:



(S,S),


(R,R),


(S,R),


(R,S),

or a mixture thereof.